Artificial Intelligence · 11.08.2026, 23:40 UTC
đŹThe BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery
| Schweregrad | info |
|---|---|
| Kategorie | Artificial Intelligence |
| Quelle | Latent Space â |
| Veröffentlicht | 11.08.2026 UTC |
Sicherheitsmeldung mit Schweregrad noch nicht bewertet. Technische Details im Tab âOriginaltextâ; empfohlene Schritte in der Checkliste.
This January, four big AI Ă Pharma tools deals were announced at the huge JPM Pharma conference that takes over San Francisco every year. OpenAI-backed Chai Discovery (now worth $4B) was somehow at the heart despite being all of 2 years old. The Science team is proud to bring you the first podcast with cofounder Matt McPartlon and product lead Neil Patil to tell the full story! Editorâs note: not to be confused with Chai AI, which was another top pod of ours.Pharma suddenly doing big AI tools dealsFor the non-pharma people, JPM is JP Morganâs annual conference for pharma deal-making that takes over San Francisco for a week in January with hundreds of side events, etc. Itâs a big thing. Tools deals for pharma are also a big (new) thing: companies that start as AI for Pharma usually end up building their own drug pipelines instead, and the reason is something like this: convincing pharma to use your tool requires proof that your tool works. Proof means good targets, maybe with good clinical validation. If you have that, then itâs easier to raise money (with a known, if long path to commercialization) or sell (e.g payment in biobucks1) for a specific target than it is to sell to lots of companies on a promise that it will work across their portfolios. The âweâll just partner / build our own drugâ optionality proved to be the only good path up until January. What changed? In short, the tools got good enough for drug design teams to trust.Good-enough-to-trust unlocks the ability to scale discovery: get more, better candidates into the lab and animal trials faster. More âŠ